Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)
China
· Delayed Price · Currency is CNY 25.87
-0.06 (-0.23%)
Apr 29, 2026, 3:04 PM CST
SHE:300357 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,083 | 1,058 | 921.46 | 840.75 | 894.88 | 804.12 | Upgrade
|
| Other Revenue | 3.92 | 3.92 | 3.94 | 7.44 | 1.14 | 3.58 | Upgrade
|
| Revenue | 1,087 | 1,062 | 925.39 | 848.19 | 896.02 | 807.69 | Upgrade
|
| Revenue Growth (YoY) | 15.91% | 14.81% | 9.10% | -5.34% | 10.94% | 26.95% | Upgrade
|
| Cost of Revenue | 50.63 | 50.58 | 44.81 | 40.19 | 42.51 | 34.44 | Upgrade
|
| Gross Profit | 1,036 | 1,012 | 880.58 | 808 | 853.5 | 773.25 | Upgrade
|
| Selling, General & Admin | 487.1 | 479.11 | 434.65 | 385.28 | 359.63 | 333.97 | Upgrade
|
| Research & Development | 112.37 | 117.1 | 119.88 | 112.2 | 106.02 | 87.93 | Upgrade
|
| Other Operating Expenses | 7.24 | 9.63 | 7.84 | 4.57 | 4.53 | 3.78 | Upgrade
|
| Operating Expenses | 610.58 | 606.46 | 563.23 | 501.05 | 471.43 | 427.23 | Upgrade
|
| Operating Income | 425.56 | 405.37 | 317.36 | 306.95 | 382.07 | 346.02 | Upgrade
|
| Interest Expense | -0.81 | -0.79 | -1.06 | -1.31 | -0.44 | -0.36 | Upgrade
|
| Interest & Investment Income | 53.52 | 26.45 | 35.81 | 32.87 | 28.35 | 29.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0 | 0 | 0 | -0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.52 | -0.32 | -0.34 | -0.26 | -0.15 | -0.17 | Upgrade
|
| EBT Excluding Unusual Items | 478.8 | 430.7 | 351.76 | 338.25 | 409.82 | 374.52 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.78 | 3.43 | 2.43 | -0.67 | -0.88 | -0.1 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.63 | 0.57 | - | -0.27 | - | Upgrade
|
| Asset Writedown | -5.11 | -5.11 | -1.42 | -0.58 | -43.23 | -0.1 | Upgrade
|
| Other Unusual Items | 2.07 | 3.06 | 11.72 | 8.95 | 33.3 | 18.67 | Upgrade
|
| Pretax Income | 480.53 | 432.71 | 365.06 | 345.96 | 398.75 | 393 | Upgrade
|
| Income Tax Expense | 67.48 | 64.62 | 60.72 | 50.43 | 63.02 | 66.71 | Upgrade
|
| Earnings From Continuing Operations | 413.05 | 368.09 | 304.34 | 295.52 | 335.73 | 326.29 | Upgrade
|
| Minority Interest in Earnings | 12.78 | 12.85 | 13.48 | 14.66 | 13.05 | 11.7 | Upgrade
|
| Net Income | 425.83 | 380.94 | 317.82 | 310.18 | 348.77 | 337.99 | Upgrade
|
| Net Income to Common | 425.83 | 380.94 | 317.82 | 310.18 | 348.77 | 337.99 | Upgrade
|
| Net Income Growth | 35.20% | 19.86% | 2.46% | -11.06% | 3.19% | 21.38% | Upgrade
|
| Shares Outstanding (Basic) | 524 | 524 | 524 | 524 | 524 | 524 | Upgrade
|
| Shares Outstanding (Diluted) | 524 | 524 | 524 | 524 | 524 | 524 | Upgrade
|
| Shares Change (YoY) | -0.01% | -0.01% | -0.00% | - | -0.00% | 0.00% | Upgrade
|
| EPS (Basic) | 0.81 | 0.73 | 0.61 | 0.59 | 0.67 | 0.65 | Upgrade
|
| EPS (Diluted) | 0.81 | 0.73 | 0.61 | 0.59 | 0.67 | 0.65 | Upgrade
|
| EPS Growth | 35.21% | 19.87% | 2.46% | -11.06% | 3.19% | 21.38% | Upgrade
|
| Free Cash Flow | 266.19 | 270.9 | 133.12 | 154.61 | 159.62 | 236.33 | Upgrade
|
| Free Cash Flow Per Share | 0.51 | 0.52 | 0.25 | 0.29 | 0.30 | 0.45 | Upgrade
|
| Dividend Per Share | 0.250 | 0.250 | 0.220 | 0.185 | 0.200 | 0.201 | Upgrade
|
| Dividend Growth | 13.64% | 13.64% | 18.92% | -7.50% | -0.50% | 25.62% | Upgrade
|
| Gross Margin | 95.34% | 95.24% | 95.16% | 95.26% | 95.25% | 95.74% | Upgrade
|
| Operating Margin | 39.16% | 38.16% | 34.29% | 36.19% | 42.64% | 42.84% | Upgrade
|
| Profit Margin | 39.18% | 35.86% | 34.34% | 36.57% | 38.92% | 41.85% | Upgrade
|
| Free Cash Flow Margin | 24.49% | 25.50% | 14.39% | 18.23% | 17.82% | 29.26% | Upgrade
|
| EBITDA | 476.93 | 455.18 | 360.94 | 338.38 | 402.44 | 366.11 | Upgrade
|
| EBITDA Margin | 43.89% | 42.84% | 39.00% | 39.89% | 44.91% | 45.33% | Upgrade
|
| D&A For EBITDA | 51.36 | 49.81 | 43.59 | 31.43 | 20.37 | 20.08 | Upgrade
|
| EBIT | 425.56 | 405.37 | 317.36 | 306.95 | 382.07 | 346.02 | Upgrade
|
| EBIT Margin | 39.16% | 38.16% | 34.29% | 36.19% | 42.64% | 42.84% | Upgrade
|
| Effective Tax Rate | 14.04% | 14.93% | 16.63% | 14.58% | 15.80% | 16.97% | Upgrade
|
| Revenue as Reported | 1,087 | 1,062 | 925.39 | 848.19 | 896.02 | 807.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.